69366JAB7
Ptc Therapeutics, Inc.
Could not find a ticker for this position, may be a filing error
A biopharmaceutical company that develops treatments for rare diseases, with medicines including Sephience for PKU, Translarna and Emflaza for Duchenne muscular dystrophy, Evrysdi for spinal muscular atrophy, and the gene therapy Upstaza/Kebilidi. Founded in 1998 by RNA researcher Stuart Peltz, the company's name comes from "post-transcriptional control," the field of RNA biology it was built around.
CONVERTIBLEUnderlying: PTCTCUSIP: 69366JAB7HealthcareUS1 derivative reporter
3.00% Convertible Senior Notes due 2022
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
